What is the maintenance dose of Xarelto (rivaroxaban) for the various indications and renal function levels?

Xarelto (Rivaroxaban) Maintenance Dosing

For atrial fibrillation, the standard maintenance dose is 20 mg once daily with the evening meal, reduced to 15 mg once daily for patients with creatinine clearance (CrCl) 15-50 mL/min. 1, 2

Dosing by Indication

Atrial Fibrillation (Stroke Prevention)

Standard dose:

• 20 mg once daily with the evening meal (CrCl >50 mL/min) 3, 1, 2

Dose reduction required:

• 15 mg once daily with the evening meal for CrCl 15-50 mL/min 3, 1, 2
• This dose reduction was prospectively studied in ROCKET-AF with 2,950 patients (21% of trial population) and demonstrated non-inferior efficacy compared to warfarin 4

Contraindications:

• End-stage renal disease or dialysis: rivaroxaban is not recommended due to lack of clinical trial evidence 1
• Severe hepatic impairment (Child-Pugh B or C): avoid use 2

Venous Thromboembolism (VTE) Treatment

Initial treatment phase (first 21 days):

• 15 mg twice daily with food 5, 6

Maintenance phase (after 21 days):

• 20 mg once daily with food 5, 6

Dose reduction for renal impairment:

• CrCl 15-50 mL/min: 15 mg once daily for maintenance treatment 1, 2
• Recent evidence supports use in severe renal impairment (CrCl 15-29 mL/min) at the 15 mg once daily dose, though this was not extensively studied in trials 7

VTE Prophylaxis After Orthopedic Surgery

Standard dose:

• 10 mg once daily 8, 9

Critical Renal Function Considerations

Monitoring frequency based on renal function: 4

• CrCl 15-30 mL/min: assess every 3 months
• CrCl 30-60 mL/min: assess every 6 months
• CrCl >60 mL/min: assess annually

Use Cockcroft-Gault formula for calculating CrCl when determining rivaroxaban dosing, not MDRD or CKD-EPI equations, as these overestimate drug removal in smaller patients and underestimate it in larger patients 4

Drug Interactions Requiring Dose Adjustment or Avoidance

Avoid concomitant use with: 10, 2

• Combined P-glycoprotein AND strong CYP3A4 inhibitors (ketoconazole, itraconazole, HIV protease inhibitors)
• Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort)

Special Populations

Elderly patients (≥75 years):

• Standard dosing applies unless renal function is impaired 10
• Recent real-world data suggests reduced-dose rivaroxaban (10 mg daily) in elderly patients with preserved renal function may increase coronary artery events compared to standard dosing 11

Gastrointestinal cancer:

• Consider alternative anticoagulation (LMWH preferred) due to increased major bleeding risk, particularly with gastric or gastroesophageal tumors 6

Common Prescribing Errors

Inappropriate underdosing is the most common error (occurring in 4.7-26.1% of patients), particularly when prescribers incorrectly apply dose reduction criteria 12. For rivaroxaban specifically, the only criterion for dose reduction in atrial fibrillation is CrCl 15-49 mL/min—not age alone, weight alone, or bleeding risk 12. Real-world studies show 25-52% of patients receive inappropriate doses, often due to "blindly continuing home dose" or misapplying criteria from other DOACs 12, 13.

Key pitfall: Do not reduce rivaroxaban dose based solely on advanced age or bleeding risk without documented renal impairment—this leads to underdosing and potential thrombotic events 12, 11.